Exciting new Parkinson’s research in Canada

Several new and innovative research projects are underway or recently completed. For example:

Dr. Michael Schlossmacher

An international study led by Dr. Michael Schlossmacher, who holds the Canada Research Chair in Parkinson’s disease at the Ottawa Hospital Research Institute and the University of Ottawa in Ottawa, has provided the first link between the most common genetic risk factor for Parkinson’s and the hallmark accumulation of a protein called alpha-synuclein within the brains of people with Parkinson’s. This study provides important new insights into Parkinson’s and paves the way for new avenues for clinical trials. Dr. Schlossmacher is a neurologist at The Ottawa Hospital and a member of the Parkinson Research Consortium. See Study provides first link between two major Parkinson’s genes.

Recruitment is underway in Quebec City, Gatineau, Ottawa, London, Saskatoon and Edmonton, for 60 men and women between 35 and 75 years old who have been diagnosed with Parkinson’s within the last two years, to participate in a phase II clinical trial to test the efficacy, safety and tolerability of CoganeTM (PYM50028) in treating early-stage Parkinson’s. Cogane is a new compound that modulates proteins in the brain that help the survival, development and function of nerve cells. The research will study whether Cogane could slow down or modify the progression of Parkinson’s. If successful, Cogane could represent a new approach to treating Parkinson’s. The study, sponsored by Phytopharm plc in the United Kingdom, is recruiting 400 participants worldwide. For more information, see Clinical Trials: Studies Seeking Participants.

Dr. Isabelle Boileau

Dr. Isabelle Boileau

At the Centre for Addiction and Mental Health in Toronto, clinical research scientist Dr. Isabelle Boileau is seeking 60 men and women with Parkinson’s over the age of 40 in the Greater Toronto Area and surrounding communities who are taking levodopa (Sinemet or generic), to participate in a brain imaging study using PET scan and MRI to understand better the relationship between long-term levodopa treatment and treatment-induced side-effects. The study is funded by Parkinson Society Canada, Ontario Mental Health Foundation and Canadian Institutes of Health Research. For more information, see Clinical Trials: Studies Seeking Participants

2 Responses to “Exciting new Parkinson’s research in Canada”


  1. 1 bruce taylor March 11, 2012 at 7:13 pm

    My mother-in-law , age 54, in Ottawa has been diagnosed with Parkinson’s. She wants to see a counsellor trained and experienced in counselling persons with Parkinson’s. Can you recommend a counsellor in the Ottawa area or even Montreal?

    Thank you.

  2. 2 Parkinson Society Canada March 12, 2012 at 11:36 am

    Thank you for connecting with us. For support in Ottawa, please connect via the Ottawa Regional website, or in Montreal, the Quebec Regional website. Please let us know if we can offer any further support.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s




Charitable registration number 10809 1786 RR0001
All material related to Parkinson's disease contained in Parkinson Post is solely for the information of the reader. It should not be used for treatment purposes. Specific articles reflect the opinion of the writer and are not necessarily the opinion of PSC.

%d bloggers like this: